282 related articles for article (PubMed ID: 30009411)
1. Fatal correlation between YAP1 expression and glioma aggressiveness: clinical and molecular evidence.
Guichet PO; Masliantsev K; Tachon G; Petropoulos C; Godet J; Larrieu D; Milin S; Wager M; Karayan-Tapon L
J Pathol; 2018 Oct; 246(2):205-216. PubMed ID: 30009411
[TBL] [Abstract][Full Text] [Related]
2. Capillary morphogenesis protein 2 is a novel prognostic biomarker and plays oncogenic roles in glioma.
Tan J; Liu M; Zhang JY; Yao YL; Wang YX; Lin Y; Song K; Tan J; Wu JR; Cui YH; Wang Y; Bian XW
J Pathol; 2018 Jun; 245(2):160-171. PubMed ID: 29473166
[TBL] [Abstract][Full Text] [Related]
3. Role of Yes-associated protein 1 in gliomas: pathologic and therapeutic aspects.
Liu YC; Wang YZ
Tumour Biol; 2015 Apr; 36(4):2223-7. PubMed ID: 25750037
[TBL] [Abstract][Full Text] [Related]
4. LGR5 promotes tumorigenicity and invasion of glioblastoma stem-like cells and is a potential therapeutic target for a subset of glioblastoma patients.
Xie Y; Sundström A; Maturi NP; Tan EJ; Marinescu VD; Jarvius M; Tirfing M; Jin C; Chen L; Essand M; Swartling FJ; Nelander S; Jiang Y; Uhrbom L
J Pathol; 2019 Feb; 247(2):228-240. PubMed ID: 30357839
[TBL] [Abstract][Full Text] [Related]
5. Expression of YAP1 and pSTAT3-S727 and their prognostic value in glioma.
Sang W; Xue J; Su LP; Gulinar A; Wang Q; Zhai YY; Hu YR; Gao HX; Li X; Li QX; Zhang W
J Clin Pathol; 2021 Aug; 74(8):513-521. PubMed ID: 33020176
[TBL] [Abstract][Full Text] [Related]
6. Proteomics reveals protein phosphatase 1γ as a biomarker associated with Hippo signal pathway in glioma.
Xue J; Sang W; Su LP; Gao HX; Cui WL; Abulajiang G; Wang Q; Zhang J; Zhang W
Pathol Res Pract; 2020 Nov; 216(11):153187. PubMed ID: 32919304
[TBL] [Abstract][Full Text] [Related]
7. Impact of MACC1 on human malignant glioma progression and patients' unfavorable prognosis.
Hagemann C; Fuchs S; Monoranu CM; Herrmann P; Smith J; Hohmann T; Grabiec U; Kessler AF; Dehghani F; Löhr M; Ernestus RI; Vince GH; Stein U
Neuro Oncol; 2013 Dec; 15(12):1696-709. PubMed ID: 24220141
[TBL] [Abstract][Full Text] [Related]
8. In silico identification of the prognostic biomarkers and therapeutic targets associated with cancer stem cell characteristics of glioma.
Lvu W; Fei X; Chen C; Zhang B
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32725165
[TBL] [Abstract][Full Text] [Related]
9. microRNA-10 and -221 modulate differential expression of Hippo signaling pathway in human astroglial tumors.
Aguennouz M; Polito F; Visalli M; Vita G; Raffa G; Oteri R; Ghazi B; Scalia G; Angileri FF; Barresi V; Caffo M; Cardali S; Conti A; Macaione V; Bartolotta M; Giorgio RD; Germanò A
Cancer Treat Res Commun; 2020; 24():100203. PubMed ID: 32777750
[TBL] [Abstract][Full Text] [Related]
10. HMGB1-RAGE signaling facilitates Ras-dependent Yap1 expression to drive colorectal cancer stemness and development.
Qian F; Xiao J; Gai L; Zhu J
Mol Carcinog; 2019 Apr; 58(4):500-510. PubMed ID: 30456802
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-622 suppresses the proliferation of glioma cells by targeting YAP1.
Xu J; Ma B; Chen G; Wei D; Li L; Hu W
J Cell Biochem; 2018 Mar; 119(3):2492-2500. PubMed ID: 28796324
[TBL] [Abstract][Full Text] [Related]
12. Chaetocin-induced ROS-mediated apoptosis involves ATM-YAP1 axis and JNK-dependent inhibition of glucose metabolism.
Dixit D; Ghildiyal R; Anto NP; Sen E
Cell Death Dis; 2014 May; 5(5):e1212. PubMed ID: 24810048
[TBL] [Abstract][Full Text] [Related]
13. Harnessing OLIG2 function in tumorigenicity and plasticity to target malignant gliomas.
Kosty J; Lu F; Kupp R; Mehta S; Lu QR
Cell Cycle; 2017 Sep; 16(18):1654-1660. PubMed ID: 28806136
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylated mTOR and YAP serve as prognostic markers and therapeutic targets in gliomas.
Liu M; Lin Y; Zhang XC; Tan YH; Yao YL; Tan J; Zhang X; Cui YH; Liu X; Wang Y; Bian XW
Lab Invest; 2017 Nov; 97(11):1354-1363. PubMed ID: 28759011
[TBL] [Abstract][Full Text] [Related]
15. Significance of perivascular tumour cells defined by CD109 expression in progression of glioma.
Shiraki Y; Mii S; Enomoto A; Momota H; Han YP; Kato T; Ushida K; Kato A; Asai N; Murakumo Y; Aoki K; Suzuki H; Ohka F; Wakabayashi T; Todo T; Ogawa S; Natsume A; Takahashi M
J Pathol; 2017 Dec; 243(4):468-480. PubMed ID: 28888050
[TBL] [Abstract][Full Text] [Related]
16. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
[TBL] [Abstract][Full Text] [Related]
17. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
18. The role of transcriptional coactivator TAZ in gliomas.
Li W; Dong S; Wei W; Wang G; Zhang A; Pu P; Jia Z
Oncotarget; 2016 Dec; 7(50):82686-82699. PubMed ID: 27764783
[TBL] [Abstract][Full Text] [Related]
19. TRIM11 is overexpressed in high-grade gliomas and promotes proliferation, invasion, migration and glial tumor growth.
Di K; Linskey ME; Bota DA
Oncogene; 2013 Oct; 32(42):5038-47. PubMed ID: 23178488
[TBL] [Abstract][Full Text] [Related]
20. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
